Hyphen Pharma International - Phillip Securities 2023-03-09: Assembling Multiple Growth Engines

• Hyphens Pharma International (SGX:1J5)'s FY22 results exceeded expectations. FY22 revenue and PATMI were 109%/118% of our forecasts. Revenue jumped across all segments in 2H22, in part driven by pent-up demand after the re-opening. Hyphens Pharma's dividend surged by 66% to 1.11 cents.
• - Read this at SGinvestors.io -
• We raise FY23e earnings forecast for Hyphens Pharma by 31% to S$13.2mil and the DCF target price for Hyphens Pharma is nudged up to S$0.445 (previously S$0.43). Our BUY recommendation is maintained.
• - Read this at SGinvestors.io -
• A near-term headwind is the upfront costs to develop the DocMed healthcare platform.

The Positive

Strong growth in specialty pharma.

• Read more at SGinvestors.io.

Above is an excerpt from a report by Phillip Securities Research.
Clients of Phillip Capital may be the first to access the full PDF report @ https://www.stocksbnb.com/.

Read also Phillip's most recent report:
2025-03-10 Hyphens Pharma International - Investing For Future Growth.

Previous report by Phillip:
2024-08-21 Hyphens Pharma International - New Products & Wider Distribution.

Price targets by 2 other brokers at Hyphens Pharma Target Prices.

Listing of research reports at Hyphens Pharma Analyst Reports.

Relevant links:
Hyphens Pharma Share Price History,
Hyphens Pharma Announcements,
Hyphens Pharma Dividend Payout Dates & Corporate Actions,
Hyphens Pharma News